Drug Profile
TTP 273
Alternative Names: TTP-273Latest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator vTv Therapeutics
- Developer vTv Therapeutics LLC
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Type 2 diabetes mellitus
- Phase I Diabetes mellitus
Most Recent Events
- 18 Dec 2023 vTv Therapeutics plans to terminates its licence for TTP 273 in China, Hong Kong, Macau, Taiwan, Thailand, Vietnam, Indonesia, Malaysia, Philippines, Singapore, Myanmar, Cambodia, Laos, Brunei, South Korea and Australia in the first half of 2024
- 21 May 2021 Phase-I clinical trials in Diabetes mellitus (Cystic fibrosis-related) in USA (PO) before May 2021 (vTv Therapeutics pipeline, May 2021)
- 31 Dec 2019 vTv Therapeutics announces intention to file application seeking orphan drug designation with US FDA for Cystic fibrosis related to diabetes mellitus